[Bupranolol eye-drops (Ophtorenin) in long-term therapy of glaucoma (author's transl)].
A clinical study with Bupranolol (Ophtorenin), a beta adrenergic blocking agent, is presented. 85 eyes with kinds species of glaucoma were treated during 22 months. A satisfying hypotensive effect was attained in a high percentage. Suitable combinations with Clonidine and Acetazolamide were tested. Based on its atoxic properties and lack of adverse reactions Bupranolol represents a valuable enlargement of glaucoma therapy.
D000086:Acetazolamide / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D002046:Bupranolol / Q000627:therapeutic use*; D003000:Clonidine / Q000627:therapeutic use; D004338:Drug Combinations; D004361:Drug Tolerance; D005260:Female; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000627:therapeutic use*; D011412:Propanolamines / Q000627:therapeutic use*
D004338:Drug Combinations; D009883:Ophthalmic Solutions; D011412:Propanolamines; D002046:Bupranolol; D003000:Clonidine; D000086:Acetazolamide
Bupranolol-Augentropfen (Ophtorenin) in der Glaukom-Dauertherapie.